Docoh
Loading...

VTYX Ventyx Biosciences

News

From Benzinga Pro
12 Health Care Stocks Moving In Wednesday's Intraday Session
8 Dec 21
Intraday Update, Markets, Movers
Ventyx Biosciences Announces First Patient Dosed In Phase 2 Clinical Trial Of VTX002 For Treatment Of Moderate-To-Severe Ulcerative Colitis
6 Dec 21
News, FDA
Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx" or the "Company"), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory
Ventyx Biosciences Q3 EPS $(3.17) Up From $(3.58) YoY
17 Nov 21
Earnings, News
Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(3.17) per share. This is a 11.45 percent increase over losses of $(3.58) per share from the same period last year.
Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021
15 Nov 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Evercore ISI Group Initiates Coverage On Ventyx Biosciences with Outperform Rating, Announces Price Target of $50
15 Nov 21
News, Price Target, Initiation, Analyst Ratings
Evercore ISI Group analyst Josh Schimmer initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Outperform rating and announces Price Target of $50.
Jefferies Initiates Coverage On Ventyx Biosciences with Buy Rating, Announces Price Target of $30
15 Nov 21
News, Price Target, Initiation, Analyst Ratings
Jefferies analyst Michael Yee initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Buy rating and announces Price Target of $30.
Piper Sandler Initiates Coverage On Ventyx Biosciences with Overweight Rating, Announces Price Target of $50
15 Nov 21
News, Price Target, Initiation, Analyst Ratings
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Overweight rating and announces Price Target of $50.
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
14 Nov 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences.
64 Biggest Movers From Yesterday
28 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
3 Stocks Insiders Are Buying
26 Oct 21
News, Small Cap, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
55 Biggest Movers From Friday
25 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
24 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, IPOs, Top Stories
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.
35 Stocks Moving In Friday's Mid-Day Session
22 Oct 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers